126550-70-7

Upstream product

• 126550-69-4 2-((R)-1-Benzyloxymethyl-pent-4-enyl)-isoindole-1,3-dione 
• 14618-80-5 (R)-benzyl glycidol 
• 155418-40-9 (2S)-1-(benzyloxy)hex-5-en-2-ol 

Downstream Products

• 138528-06-0 (2S,5S)-5-benzyloxymethyl-1-tert-butoxycarbonyl-2-hydroxymethylpyrrolidine 
• 126550-72-9 (2S,5S)-2-benzyloxymethyl-5-benzoyloxymethylpyrrolidine 
• 126550-74-1 (2R,5S)-1-tert-butoxycarbonyl-2-benzyloxymethyl-5-benzyloxymethylpyrrolidine 
• 126550-73-0 N-Boc-2-(S)-benzoyloxymethyl-5-(S)-benzyloxy methylpyrrolidine 
• 81702-31-0 (2S,5S)-pyrrolidine-2,5-dicarboxylic acid 
• 126550-71-8 (S)-1-benzyloxy-2-benzoylaminohex-5-ene 

Relevant academic research and scientific papers

VLA-4 inhibitor compounds

Compounds that selectively inhibit the binding of ligands to alpha4beta1 integrin (VLA-4) and methods for their preparation are disclosed. In one embodiment, compounds of the invention are represented by Formula I: As selective inhibitors of VLA-4 mediated cell adhesion, compounds of the present invention are useful in the treatment of conditions associated with such adhesion, including, but not limited to, such conditions as inflammatory and autoimmune responses, diabetes, asthma, psoriasis, inflammatory bowel disease, transplantation rejection, and tumor metastasis. Also disclosed are pharmaceutical compositions, methods of inhibiting VLA-4 mediated cell adhesion and methods of treating conditions associated with LA-4 mediated cell adhesion, which involve compounds of Formula I.

CONCISE SYNTHESIS OF C2-SYMMETRIC TRANS-2,5-DIOXYMETHYLPYRROLIDINE DERIVATIVES BY NOVEL CYCLIZATION

Treatment of (S)-1-benzyloxy-2-benzoylaminohex-5-ene with iodine in aqueous acetonitrile furnished (2S,5S)-5-benzoyloxymethyl-2-bemzyloxymethylpyrrolidine stereoselectively in a single step.The product was converted into C2-symmetric (2S,5S)-2,5-dioxymethylpyrrolidines potentially utilizable as chiral auxiliaries and (2S,5S)-(-)-pyrrolidine-2,5-dicarboxylic acid isolated from marine alga Schizymenia dubyi.